References
- Mantha S, Cabral K, Ansell J. New avenues for anticoagulation in atrial fibrillation. Clin Pharmacol Ther 2013;93:68-77
- Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics – 2013 update: a report from the American Heart Association. Circulation 2013;127:e6-245
- Wattigney WA, Mensah GA, Croft JB. Increasing trends in hospitalization for atrial fibrillation in the United States, 1985 through 1999: implications for primary prevention. Circulation 2003;108:711-16
- Mercaldi CJ, Ciarametaro M, Hahn B, et al. Cost efficiency of anticoagulation with warfarin to prevent stroke in Medicare beneficiaries with nonvalvular atrial fibrillation. Stroke 2011;42:112-18
- Hankey GJ, Eikelboom JW. Novel oral anticoagulants for atrial fibrillation. Curr Atheroscler Rep 2013;15:344
- Clayville LR, Anderson KV, Miller SA, et al. New options in anticoagulation for the prevention of venous thromboembolism and stroke. P T 2011;36:86-99
- Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007;146:857-67
- Mittmann N, Henry B, Murshed S, et al. Does warfarin use impact hospital length of stay? A retrospective study looking at patients treated for atrial fibrillation. Hosp Top 2013;91:20-4
- Song X, Sander SD, Johnson BH, et al. Impact of atrial fibrillation and oral anticoagulation on hospital costs and length of stay. Am J Health Syst Pharm 2012;69:329-38
- Tan ES, Bonnett TJ, Abdelhafiz AH. Delayed discharges due to initiation of warfarin in atrial fibrillation: a prospective audit. Am J Geriatr Pharmacother 2007;5:232-5
- Fonseca E, Walker DR, Hill J, Hess GP. Dabigatran etexilate is associated with shorter hospital length of stay compared to warfarin in patients with nonvalvular atrial fibrillation. Circ Cardiovasc Qual Outcomes 2012;5:A282
- Fonseca E, Walker DR, Hess GP. Dabigatran etexilate is associated with shorter hospital length of stay and lower hospital costs compared to warfarin in treatment-naive, newly-diagnosed nonvalvular atrial fibrillation patients. Circ Cardiovasc Qual Outcomes 2013;6:A258
- Fox BD, Kahn SR, Langleben D, et al. Efficacy and safety of novel oral anticoagulants for treatment of acute venous thromboembolism: direct and adjusted indirect meta-analysis of randomised controlled trials. BMJ 2012;345:e7498
- Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883-91
- Cohen J. Statistical Power Analysis for the Behavioral Sciences. Toronto: Academic Press Inc., 1977:19-74
- Normand ST, Landrum MB, Guadagnoli E, et al. Validating recommendations for coronary angiography following acute myocardial infarction in the elderly: a matched analysis using propensity scores. J Clin Epidemiol 2001;54:387-98
- Austin P. Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research. Comm Stat Simulat Comput 2009;38:1228-34
- Joint Commission. 2013 National Patient Safety Goals. Available at: http://www.jointcommission.org/assets/1/18/NPSG_Chapter_Jan2013_HAP.pdf [Last accessed 29 July 2013]
- Plowman R, Graves N, Griffin MA, et al. The rate and cost of hospital-acquired infections occurring in patients admitted to selected specialties of a district general hospital in England and the national burden imposed. J Hosp Infect 2001;47:198-209
- Eber MR, Laxminarayan R, Perencevich EN, et al. Clinical and economic outcomes attributable to health care-associated sepsis and pneumonia. Arch Intern Med 2010;170:347-53